Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878756 | 0.87 | CRHR1 (0.55) | CRHR1SCN9ARUNX1GPR3LMNA | |
| SCHEMBL4626672 | 0.86 | CRHR1 (0.48) | CRHR1SCN9ARUNX1GPR3LMNA | |
| SCHEMBL4885439 | 0.84 | CRHR1 (0.56) | CRHR1RUNX1 | |
| SCHEMBL4885196 | 0.83 | CRHR1 (0.60) | CRHR1SCN9ARUNX1 | |
| SCHEMBL4881928 | 0.82 | CRHR1 (0.54) | CRHR1SCN9ARUNX1CHRM5 | |
| SCHEMBL6607143 | 0.82 | CRHR1 (0.54) | CRHR1SCN9ARUNX1 | |
| SCHEMBL14183041 | 0.82 | CRHR1 (0.56) | CRHR1SCN9A | |
| SCHEMBL4884829 | 0.82 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL5406519 | 0.82 | CRHR1 (0.68) | CRHR1SCN9ARUNX1 | |
| SCHEMBL4878160 | 0.79 | CRHR1 (0.53) | CRHR1SCN9ARUNX1GPR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1392302-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | NEUROGEN CORPORATION | 2003-08-14 | — | — | US | disclosed |
| WO-2002096421-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | HTR5A, CRHR2, HTR2C | CRHR1 5/4885SCN9A 3544/4885RUNX1 1770/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | CRHR1 2/4885SCN9A 3903/4885RUNX1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.